AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35449368
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg olanzapine plus tropisetron and dexamethasone (omitting aprepitant)
Trial: 33355079
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen (Group A): omeprazole, amoxicillin, clarithromycin, and bismuth subcitrate for 2 weeks.
Trial: 34935724
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of damask rose 40% and lavender 10% essential oils
Trial: 33121289
Drug: 0.5 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/d melatonin plus 30 minutes of 10,000 lux bright light therapy (BLT)
Trial: 33601849
Drug: Anti-Toxoplasma antibodies
RxNorm normalized name: Toxoplasma gondii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Toxoplasma antibodies (IgM) testing
Trial: 33601849
Drug: Avidity test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avidity test for IgG antibodies
Trial: 34849690
Drug: Local gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local gentamicin treatment (collagenous carriers containing gentamicin left between sternal halves during sternal refixation)
Trial: 33198568
Drug: Acupuncture (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (twice a week for 4 weeks + conventional therapy)
Trial: 32658385
Drug: Hyperinsufflation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsufflation therapy (15 minutes twice daily using a cough assist device over 12 months)
Trial: 32658385
Drug: Hyperinsufflation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsufflation therapy
Trial: 34151671
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pill (OCP) from the first day of the cycle to five days before starting ovarian stimulation
Trial: 34151671
Drug: 2 mg/12
RxNorm normalized name: Kapvay, 0.2 mg/12 hr oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/12 hours of oral E2 valerate from day 25 of the previous cycle until the day before starting stimulation
Trial: 34496087
Drug: Nanomicelle curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanomicelle curcumin (CUR) 80 mg
Trial: 34496087
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa oil (NS) 1,000 mg
Trial: 34496087
Drug: CUR (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CUR (80 mg) and NS (1,000 mg)
Trial: 34497110
Drug: Ertugliflozin (pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin (pooled doses)
Trial: 32780926
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 µg/kg over 10 minutes, 0.5 µg/kg/h during surgery, and 1 µg/kg after cardiopulmonary bypass)
Trial: 36344766
Drug: Fenofibrate 145
RxNorm normalized name: fenofibrate 145 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 145 mg oral nanocrystal formulation for 10 days
Trial: 32652024
Drug: 6 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g/d of long-chain triglycerides (LCT group)
Trial: 32652024
Drug: LD +
RxNorm normalized name: Children's Tylenol Cold + Flu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LD + MCT group (1.2 g L-leucine and 20 μg cholecalciferol enriched with 6 g/d of MCTs)
Trial: 32326727
Drug: Yoga therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga therapy for 12 weeks
Trial: 35534825
Drug: Esketamine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine 0.2 mg/kg
Trial: 35380740
Drug: Tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 10 mg b.i.d.
Trial: 35380740
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg b.i.d.
Trial: 33214446
Drug: Preoperative hepatic
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative hepatic and regional arterial chemotherapy (PHRAC) plus adjuvant therapy
Trial: 33214446
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy alone (control)
Trial: 32936427
Drug: TRZ30 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRZ30 (10 mg three times daily for 8 weeks)
Trial: 32936427
Drug: TRZ60 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRZ60 (20 mg three times daily for 8 weeks)
Trial: 34938354
Drug: Bisphosphonate drugs
RxNorm normalized name: Bisphosphonate drugs affecting bone structure and mineralization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonate drugs
Trial: 35432844
Drug: Insulin combined
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin combined with Traditional Chinese Medicine (TCM) prescription
Trial: 35432844
Drug: Nursing intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nursing intervention based on control group (Insulin + TCM)
Trial: 33168910
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (antibiotics)
Trial: 35643873
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein yogurt (10 g protein/100 g)
Trial: 35643873
Drug: Normal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal protein yogurt (3.5 g protein/100 g)
Trial: 34673449
Drug: Computer-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-based therapy
Trial: 34673449
Drug: Therapist-mediated therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-mediated therapy
Trial: 36592517
Drug: 0.1 mg/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/L Schisandrin B
Trial: 36592517
Drug: 0.5 mg/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/L Schisandrin B
Trial: 33772456
Drug: Pentoxiphylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxiphylline (PTX) and Vitamin E (VE) combination (PTVE group)
Trial: 32615392
Drug: Probiotics (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (6 g/d for 6 months)
Trial: 32615392
Drug: Synbiotics (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotics (6 g/d for 6 months)
Trial: 32615392
Drug: Placebo (maltodextrin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin, 6 g/d for 6 months)
Trial: 35645564
Drug: Congruence Couple
RxNorm normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Congruence Couple Therapy (CCT)
Trial: 35645564
Drug: Treatment‐as‐Usual (TAU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment‐as‐Usual (TAU)
Trial: 34985236
Drug: Sham manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham manual therapy technique (CG)
Trial: 32641470
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium 440 mg
Trial: 33906234
Drug: ALB (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALB (400 mg) plus IVM (600 μg/kg) for 3 consecutive days
Trial: 34872341
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis combined with EVT (combination-therapy group)
Trial: 35226099
Drug: Low-dose rh
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rh insulin (400-μIU/mL milk)
Trial: 35226099
Drug: High-dose rh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rh insulin (2000-μIU/mL milk)
Trial: 33750266
Drug: Probiotic acidophilus
RxNorm normalized name: Probiotic Acidophilus 1mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic acidophilus milk (100 g/day, 107 cfu/g)
Trial: 33750266
Drug: Freshly prepared
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freshly prepared 'dahi' (100 g/day, 107 cfu/g)
Trial: 33750266
Drug: Thermal processed
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal processed buffalo milk (100 ml/day)
Trial: 32683390
Drug: Topical gel
RxNorm normalized name: Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel containing 0.2% chlorhexidine, 0.5% chitosan, 5% dexpanthenol, 0.15% allantoin, and 0.01% sodium saccharin
Trial: 32007714
Drug: Stabilising chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stabilising chemotherapy
Trial: 33260292
Drug: Strong parental
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strong parental support for breakfast as the main daily meal
Trial: 36309950
Drug: Carbidopa doses
RxNorm normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbidopa doses with 200 mg entacapone
Trial: 33450160
Drug: Laparoscopic adrenalectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic adrenalectomy (LA-g)
Trial: 34093444
Drug: Levothyroxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine treatment
Trial: 34716902
Drug: RIST4721 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIST4721 300 mg once daily for 28 days
Trial: 35768027
Drug: Treatment received
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment received by patients
Trial: 32945860
Drug: Gamified ICTs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamified ICTs (42 daily and 2 weekly sessions)
Trial: 32945860
Drug: Nongamified ICTs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nongamified ICTs (42 daily and 2 weekly sessions)
Trial: 35355249
Drug: KHKi 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KHKi 50 mg once daily
Trial: 35355249
Drug: KHKi alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KHKi alone (100–600 mg)
Trial: 34428929
Drug: non-ACE/ARB treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-ACE/ARB treatment
Trial: 35199834
Drug: 1000 mg/d
RxNorm normalized name: RibaTab 1000 MG/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/d DHA (experimental group: EXP)
Trial: 36185549
Drug: Upadacitinib 15
RxNorm normalized name: upadacitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 15 mg plus topical corticosteroids (TCS)
Trial: 36185549
Drug: Upadacitinib 30
RxNorm normalized name: upadacitinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 30 mg plus topical corticosteroids (TCS)
Trial: 36185549
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus topical corticosteroids (TCS)
Trial: 35411924
Drug: Synbiotic yogurt
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic yogurt (SYN) containing inulin (4 g) and Lactobacillus rhamnosus GG (>1 × 10^7 CFU/mL)
Trial: 34127095
Drug: Cariprazine (3-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine (3-12 mg/d, 3-6 mg/d, or 6-12 mg/d for 3 weeks)
Trial: 34766785
Drug: laboratory alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: laboratory alcohol self-administration
Trial: 36343645
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004 (10-360 mg once daily for 14 days)
Trial: 36343645
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004 (≥40 mg once daily for 14 days)
Trial: 32046452
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg daily + COC containing drospirenone for 21 days
Trial: 35926795
Drug: Periarticular Injection
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular Injection (PAI)
Trial: 33205362
Drug: Daridorexant 50
RxNorm normalized name: daridorexant 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daridorexant 50 mg with ethanol
Trial: 33205362
Drug: Daridorexant 50
RxNorm normalized name: daridorexant 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daridorexant 50 mg alone
Trial: 33747081
Drug: Tricyclic antidepressants
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressants (TCA)
Trial: 32762161
Drug: gonadotrophin releasing
RxNorm normalized name: Gonadotrophin releasing factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gonadotrophin releasing hormone analogue (GnRHa)
Trial: 32338316
Drug: Oral ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ondansetron
Trial: 33678106
Drug: Tildrakizumab 100
RxNorm normalized name: tildrakizumab 100 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tildrakizumab 100 mg at weeks 0, 4, 16, and 28
Trial: 33678106
Drug: Tildrakizumab 100
RxNorm normalized name: tildrakizumab 100 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tildrakizumab 100 mg at week 4
Trial: 33678106
Drug: Tildrakizumab 100
RxNorm normalized name: tildrakizumab 100 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tildrakizumab 100 mg at week 16
Trial: 35943798
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg twice a day
Trial: 37490202
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg every 2 weeks
Trial: 35167999
Drug: Prickly Pear
RxNorm normalized name: Prickly Pear Fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prickly Pear juice (250 mL; 45 mg betalain content; reduced fiber)
Trial: 33038062
Drug: E6011 400/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6011 400/200 mg
Trial: 33038062
Drug: E6011 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6011 100 mg (in subgroup with higher baseline CD16+ monocytes)
Trial: 33038062
Drug: E6011 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6011 200 mg (in subgroup with higher baseline CD16+ monocytes)
Trial: 33038062
Drug: E6011 400/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6011 400/200 mg (in subgroup with higher baseline CD16+ monocytes)
Trial: 34134579
Drug: Adalimumab injecta
RxNorm normalized name: adalimumab Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab injecta (40 mg)
Trial: 34134579
Drug: Humira® (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humira® (40 mg)
Trial: 35057579
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral glucose tolerance test (OGTT))
Trial: 34758210
Drug: Peer-delivered group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer-delivered group cognitive-behavioral therapy (CBT) for postpartum depression (PPD)
Trial: 32350679
Drug: Breast Conservation
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast Conservation Therapy (BCT)
Trial: 34633116
Drug: Romosozumab 210
RxNorm normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romosozumab 210 mg sc every month for 2 months
Trial: 35599000
Drug: Prasugrel (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (3.75 mg/day)
Trial: 36286886
Drug: Bismuth-based quadruple
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-based quadruple therapy with Bifiform (omeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bismuth tripotassium dicitrate 240 mg, Bifiform 2 capsules 2 times a day for 14 days)
Trial: 36286886
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group therapy (same as main group but without Bifiform)
Trial: 33277803
Drug: Platelet count
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet count (PLT) > 105 × 10^9/L
Trial: 34559394
Drug: Low-dose hydrocortisone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hydrocortisone (10 mg)
Trial: 34253806
Drug: Cold bubbled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold bubbled humidified oxygen therapy (OX + HUMID)
Trial: 34253806
Drug: Dry oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry oxygen therapy (OX + DRY)
Trial: 35576384
Drug: Antibiotics (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (intravenous ertapenem followed by oral levofloxacin and metronidazole)
Trial: 33752446
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) (n = 37)
Trial: 33781638
Drug: Closed-incision negative-pressure
RxNorm normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-incision negative-pressure therapy (ciNPT)
Trial: 34474584
Drug: Drug-Eluting Balloons
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Eluting Balloons (DEB)
Trial: 33509845
Drug: Antibiotic-loaded bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-loaded bone cement (ALBC)
Trial: 35932699
Drug: Betta fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betta fish therapy (kept at home for 2 months)
Trial: 33395924
Drug: Salbutamol (SAL)
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol (SAL) 400 µg
Trial: 32043907
Drug: Inotersen 300
RxNorm normalized name: INOTERSEN
DrugBank: Inotersen (DB14713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inotersen 300 mg/week
Trial: 33851246
Drug: Outpatient physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient physical therapy (superficial heater + deep heater + transcutaneous electrical nerve stimulation) for 2 weeks and spa therapy
Trial: 33851246
Drug: Inpatient physical
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient physical therapy (superficial heater + deep heater + transcutaneous electrical nerve stimulation) for 2 weeks and spa therapy
Trial: 32234653
Drug: High-protein formula
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein formula (2.1 g protein/100 kcal)
Trial: 32740903
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium valproate (iVPA)
Trial: 32125665
Drug: Finerenone 20
RxNorm normalized name: finerenone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenone 20 mg orally
Trial: 33583360
Drug: Cecolin® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cecolin® vaccine (high ISAR score)
Trial: 32562682
Drug: Medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical management plus interventional therapy
Trial: 34609621
Drug: PROT (advice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PROT (advice to increase protein intake to ≥ 1.2 g/kg aBW/d)
Trial: 33509352
Drug: Short taper
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short taper of steroids over 36 days after remission
Trial: 32326966
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (HSP, HSP+, Casein)
Trial: 37366571
Drug: Antiarrhythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drugs (AAD)
Trial: 33653815
Drug: Antidiabetic drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidiabetic drug users (including insulin and metformin)
Trial: 33653815
Drug: Antidiabetic drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidiabetic drug users
Trial: 34914216
Drug: Tadalafil combined
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil combined with behavioral therapy and psychological counseling
Trial: 32252716
Drug: Guideline Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline Daily Amounts (GDA)